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Abstract
Background: Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of the
human immunodeficiency virus (HIV). The PROUD study found that PrEP conferred higher protection than in
placebo-controlled trials, reducing HIV incidence by 86 % in a population with seven-fold higher HIV incidence
than expected. We present the baseline characteristics of the PROUD study population and place the findings in
the context of national sexual health clinic data.
Methods: The PROUD study was designed to explore the real-world effectiveness of PrEP (tenofovir-emtricitabine) by
randomising HIV-negative gay and other men who have sex with men (GMSM) to receive open-label PrEP immediately
or after a deferral period of 12 months. At enrolment, participants self-completed two baseline questionnaires collecting
information on demographics, sexual behaviour and lifestyle in the last 30 and 90 days. These data were compared to
data from HIV-negative GMSM attending sexual health clinics in 2013, collated by Public Health England using
the genitourinary medicine clinic activity database (GUMCAD).
Results: The median age of participants was 35 (IQR: 29–43). Typically participants were white (81 %), educated at a
university level (61 %) and in full-time employment (72 %). Of all participants, 217 (40 %) were born outside the UK. A
sexually transmitted infection (STI) was reported to have been diagnosed in the previous 12 months in 330/515 (64 %)
and 473/544 (87 %) participants reported ever having being diagnosed with an STI. At enrolment, 47/280 (17 %)
participants were diagnosed with an STI. Participants reported a median (IQR) of 10 (5–20) partners in the last 90 days,
a median (IQR) of 2 (1–5) were condomless sex acts where the participant was receptive and 2 (1–6) were condomless
where the participant was insertive. Post-exposure prophylaxis had been prescribed to 184 (34 %) participants in the
past 12 months. The number of STI diagnoses was high compared to those reported in GUMCAD attendees.
Conclusions: The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the
overall population of GMSM attending sexual health clinics in England. These findings contribute to explaining the
extraordinary HIV incidence rate during follow-up and demonstrate that, despite broad eligibility criteria, the
population interested in PrEP was highly selective.
Trial registration: Current Controlled TrialsISRCTN94465371. Date of registration: 28 February 2013.
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Background
Pre-exposure prophylaxis (PrEP) has proven biological
efficacy to reduce the sexual acquisition of human im-
munodeficiency virus (HIV). In 2012 the US Food and
Drugs Administration approved the use of daily Truvada
(tenofovir and emtricitabine) as PrEP [1] based on several
placebo-controlled randomised trials [2–4].
In England, gay and other men who have sex with
men (GMSM) are the population most likely to acquire
HIV sexually, according to surveillance data routinely
collected from sexual health clinics. Using the CD4 back
calculation estimate of HIV incidence, 2470 men who
have sex with men (MSM) were estimated to have ac-
quired their HIV infection in the UK in 2013. This num-
ber has increased steadily from 2004 and now accounts
for 51 % of all new HIV infections [5].
In addition to its biological benefits, the clinical delivery
of PrEP currently requires contact with clinical services to
enable regular testing for HIV and sexually transmitted in-
fections (STIs), as well as access to behavioural interven-
tions. Modelling suggests that introducing PrEP would
have a large impact on the UK epidemic [6], in the context
of provision to an appropriate population [7].
In England, sexual health for GMSM at risk of HIV is
primarily provided by a network of over 200 open-access
free clinics with 92,037 HIV-negative GMSM attending
in 2013. To roll out PrEP in this setting, evidence of
effectiveness that takes account of any change in risk be-
haviour is required [8]. This could only be captured in
an open-label trial without a placebo control, ideally
within a schedule and in a setting where PrEP could be
delivered realistically (in terms of capacity and resources)
[9]. Factors that could limit the population effectiveness of
PrEP include changes in sexual behaviour [10] and the
emergence of drug resistance [11]. In a nationally funded
health service, it is also essential to consider the potential
impact of funding diversion on other prevention activities
and delivery of clinical services [12, 13].
The PROUD study demonstrated that the inclusion of
PrEP gave a relative reduction of 86 % in the incidence
of HIV, with no infections among participants taking
PrEP, and refuted concerns that real-world effectiveness
would be compromised [14]. HIV incidence in the study
population was shown to be approximately seven times
higher than the estimate for GMSM attending sexual
health clinics in 2012. Here we present the baseline char-
acteristics of the PROUD study population and place the
findings in the context of national data returned from the
sexual health clinics.
Methods
The PROUD trial was designed to explore the real-world
effectiveness of PrEP in which eligible HIV-negative
GMSM received open-label tenofovir-emtricitabine (TDF-
FTC) either immediately, in a risk reduction package, or
after a deferral period of 12 months follow-up. The
intention was of implementing this in sexual health
clinics and with study procedures as close as possible
to routine care in this setting. This paper reports the
characteristics of participants recruited during a pilot
phase, which aimed to establish the feasibility of a
complete trial. However, the unexpectedly large num-
ber of HIV infections during the deferral period led to
a recommendation from the Trial Steering Committee
in October 2014 that all participants be offered PrEP.
The findings on the effectiveness of PrEP were pub-
lished and a larger trial is no longer required [14]. Trial
procedures during the study are described in detail
elsewhere [14].
The anticipated target for an adequately powered trial
was 5000 (2500 per arm). This was based on an esti-
mated incidence of 3/100 person-years during the first
year in participants who were waiting to access Truvada
and a 50 % reduction in incidence in those offered
Truvada. An arbitrary 10 % target of 500 for the pilot
phase was a pragmatic choice to guide as to whether
5000 participants could be enrolled over 2 years, according
to the eligibility criteria in Table 1.
Potentially eligible GMSM were identified during rou-
tine attendances at 13 sexual health clinics in England,
8 in London and 5 outside (Birmingham, Brighton,
Manchester, Sheffield and York). Participants with
Table 1 Eligibility requirements
Inclusion criteria Exclusion criteria
1. Born to male gender, age 18 years or older
2. Previously attended the enrolling clinic on at least one occasion
3. Completed a screen for HIV and STIs
4. HIV-negative by a routinely used assay within
4 weeks prior to or on the day of randomisation
5. Reported unprotected anal intercourse (UAI) on more than
one occasion within the 90 days prior to randomisation
6. Likely, in the opinion of the volunteer, to have UAI in the next 90 days
7. Willing and able to comply with the visit schedule throughout the
follow-up period
8. Willing and able to provide written informed consent
1. An acute viral illness that could be due to HIV seroconversion
2. Any contraindications to Truvada according to the current
package insert
3. Treatment for hepatitis B infection indicated or ongoing
4. Unlikely, in the opinion of the clinician, to comply with the
randomised allocation
HIV human immunodeficiency virus, STI sexually transmitted infection
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regular sexual partners (in the opinion of the potential
volunteer) who also met eligibility requirements were
encouraged to enrol at the same time and both partners
were randomly allocated to the same trial arm, mini-
mising the possibility of PrEP being shared. Posters and
electronic screens in participating sexual health clinics,
as well as advertisements on social media, helped to
promote the study. Business cards and leaflets advertising
the study were also handed out by community organisa-
tions during outreach activities, including efforts to raise
awareness of PrEP amongst GMSM. There was no finan-
cial payment for participants joining the study, nor were
travel costs or other expenses paid for.
A screening visit was not required as the eligibility
data on HIV are collected routinely. The Participant
Information Sheet was shared with volunteers prior to
enrolment. The research team at the clinic determined
eligibility through a structured discussion with the volun-
teer and written informed consent was collected prior to
enrolment. Eligible participants were randomised using a
web-based tool incorporated within the database at each
clinic. At the enrolment visit participants were asked to
self-complete, in private, two paper baseline question-
naires (Additional files 1 and 2) on separate booklets
collecting information on: demographics, sexual behaviour
and lifestyle in the last 30 and 90 days; perception of HIV
risk at the last condomless sex act; risk management
strategies; past history of STIs; drug and alcohol use;
depression severity captured by the Patient Health
Questionnaire-9 (PHQ-9) [15]; motivation for taking
part in the study; and perceptions regarding adherence
to taking a daily pill. The questionnaires were derived
from other studies in MSM populations and were being
tested as part of the pilot phase. Questionnaires took
less than 30 minutes to complete and were placed in a
sealable envelope and sent to the Medical Research
Council Clinical Trials Unit (MRC CTU) at University
College London (UCL) for data entry without clinic
staff seeing the responses.
A screen for STIs was performed, if indicated, according
to routine clinical practice. A sample for antibody/antigen
HIV testing was collected on the day of enrolment
(Table 1).
In NHS sexual health clinics, basic demographic, diag-
nostic and service data are also returned for each attend-
ance and collated by Public Health England, using the
genitourinary medicine clinic activity database version 2
(GUMCADv2). GUMCADv2 is a pseudo-anonymised
patient-level electronic dataset collecting information on
diagnoses made and services provided by genitourinary
medicine (GUM) clinics (level 3) and other commis-
sioned level 2 (non-GUM) sexual health services [16].
For this analysis, data were extracted from GUMCADv2
on GMSM who were HIV-negative or of unknown status
from all clinics in England between January 2013 and
December 2013. Data were extracted on key demo-
graphics including age, ethnicity and place of birth, STI
diagnoses by number of GMSM, as opposed to by GMSM
attendances, (pharyngeal, urethral and rectal chlamydia
and gonorrhoea, primary secondary and early latent
syphilis, hepatitis B and C infections, lymphogranuloma
venereum (LGV)), HIV tests (number of HIV tests and
average number per GMSM), and episodes of post-
exposure HIV prophylaxis (PEP) among GMSM.
The data were analysed using Stata 13.1 [17]. Compari-
sons of categorical data were conducted using a χ2 test or
a two-tailed Fisher exact test where numbers were less
than five in any group. Participants recruited within
London were compared to those recruited outside of
London to determine differences in baseline demo-
graphics, sexual behaviour and lifestyle. Continuous
variables were compared using a Mann-Whitney U test.
Multiple component analysis (MCA) was used to deter-
mine whether responses to questions where participants
could select multiple answers decomposed into distinct
groups [18].
The PROUD study protocol was approved by London
Bridge Research Ethics Committee, the Medicines and
Healthcare products Regulatory Agency and each partici-
pating hospital trust (Chelsea and Westminster Healthcare
NHS Foundation Trust, London, UK; Brighton and Sussex
University Hospitals NHS Trust, Brighton, UK; Homerton
University Hospital NHS Foundation Trust, London, UK;
Central Manchester University Hospitals NHS Foundation
Trust, Manchester, UK; Imperial College Healthcare NHS
Foundation Trust, London, UK; Sheffield Teaching Hospi-
tals NHS Foundation Trust, Sheffield, UK; York Teaching
Hospital and Hull York Medical School, York, UK; Barts
Health NHS Trust, London, UK; King’s College Hospital
NHS Foundation Trust, London, UK; Guy’s and St Thomas’
NHS Foundation Trust, London, UK; and Heart of England
NHS Foundation Trust, Birmingham, UK).
Results
Recruitment
The PROUD pilot study enrolled the first participant on
27 November 2012. The pilot study was initially ex-
pected to fully recruit within 6 months, but this target
was modified in April 2013 due to slow recruitment, at-
tributed to lack of study resources delaying clinic activa-
tion, and low awareness of PrEP in the community [19].
The modified target was that full recruitment would be
reached in April 2014. The two cumulative targets and
actual recruitment are shown in Fig. 1. Recruitment was
stopped at the end of April 2014 after 544 participants
were enrolled. Two participants enrolled twice to access
PrEP and were analysed in their original trial arm, the
deferred group (Fig. 2). In total, 19 participants enrolled
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with their partner in the trial and were randomised to
the same trial arm.
Baseline demographics
Data from the self-completed questionnaire were avail-
able for 540/544 participants (99 %); missing question-
naires were either lost (n = 3) or not completed by
participants (n = 1).
Baseline demographic data are shown in Table 2. The
median age of participants was 35 (interquartile range
(IQR): 29–43) with an age range of 18–75, and the
majority of participants were of white ethnicity (81 %).
Participants who described themselves as of an ‘Other’
ethnicity defined themselves as Chinese (n = 11), Latin
American (n = 10), Arabic (n = 5), Asian (n = 5) or mixed
race or other (n = 5).
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546
participants 
2 randomly 
assigned twice
544 eligible 
individuals
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immediate group
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273 baseline 
questionnaire available
267 baseline 
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2 questionnaires 
lost
1 questionnaire lost
1 not completed
2 HIV positive at 
enrolment
1 HIV positive at 
enrolment
Fig. 2 Flow diagram of enrolment
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Typically participants were highly educated, 61 % were
educated at a university degree level or above. Participants
were predominantly employed either full-time (72 %) or
part-time (10 %). Of all participants, 217 (40 %) were born
outside the UK. In total, 156 (29 %) participants were cir-
cumcised and circumcision was significantly higher in par-
ticipants born outside the UK (n = 84; 39 % versus n = 72;
23 %; p <0.001). The majority of participants described
their sexuality as gay/homosexual (n = 514; 95 %), 16 (3 %)
as bisexual and 6 (1 %) as straight/heterosexual. Only one
participant defined themselves as transgender. A preva-
lence rate for moderate to high severity of depressive
symptoms of 9.5 % was identified, lower than those
observed in HIV-1-positive MSM in the Antiretrovirals,
Sexual Transmission Risk and Attitudes (ASTRA) study
(27.0 %) [20]. The prevalence of a major depressive dis-
order was 5.0 %, higher than the 2.5 % observed in a
general European male population [21]. Almost half
(46 %) of the participants described themselves as
being in an ongoing relationship and 160 (30 %) were
currently living with their partner.
Sexually transmitted infections
STI data from the clinic interview (self-reported lifetime
diagnoses), self-completed questionnaire (self-reported
diagnoses in the last 12 months) and baseline STI test
are shown in Table 3. Self-reported data on STI history
were available for 515/544 (94 %) participants but the
exact denominators differed by STI. A diagnosis of any
STI in a participant’s lifetime was reported in 473/544
(87 %) participants. This was frequently urethral gonor-
rhoea (n = 216; 40 %), oral gonorrhoea (n = 175; 32 %),
rectal gonorrhoea (n = 174; 33 %), urethral chlamydia
(n = 173; 32 %) and genital warts (n = 168; 31 %). Par-
ticipants reported being screened for STIs a median
(IQR) of 3 (2–4) times in the previous 12 months. One
or more STI diagnoses in the previous 12 months was
reported in 330/515 (64 %) participants, in particular: rec-
tal gonorrhoea (n = 126; 26 %), oral gonorrhoea (n = 121;
25 %), urethral gonorrhoea (n = 112; 24 %) and rectal
chlamydia (n = 99; 21 %). At enrolment 47/280 (17 %)
participants screened, based on clinical indication, were
diagnosed with an STI. These were mostly oral gonor-
rhoea (n = 13), syphilis (n = 13), rectal gonorrhoea (n = 12)
and rectal chlamydia (n = 10) diagnoses. In addition, three
participants were found to be HIV-1-positive despite
having an HIV-negative test in the 4 weeks prior to ran-
domisation. These participants are included in these ana-
lyses of baseline data.
Reported sexual risk management strategies and
risk perception
Participants had attended a clinic a median (IQR) of 3
(2–4) times in the past 12 months for an HIV test. A
Table 2 Baseline demographic data
Number %
Age
18–25 54 10
25–35 210 39
35–45 178 33
>45 98 18
Ethnicity
White/Irish 439 81
Indian/Pakistani/Bangladeshi 18 4
Black Caribbean/Black-African/Other 21 4
Mixed ethnic group 24 4
Other 36 7
Missing 2 0
Born in UK
Noa 217 40
Yes 322 60
Missing 1 0
Sexuality
Gay/homosexual 514 95
Bisexual 16 3
Straight/heterosexual 6 1
Missing 4 1
Maximum education
No qualifications 14 3
O-levels/GCSEs/Equivalent 60 11
A-levels/Equivalent 87 16
University degree or above 327 61
Still in full-time education 19 4
Vocational training/Other qualifications 32 6
Missing 1 0
Circumcised
No 380 70
Yes 156 29
Missing 4 1
PHQ-9 depression severity
Minimal 381 71
Mild 88 16
Moderate 27 5
Moderately severe 16 3
Severe 6 1
Missing 22 4
Current relationship status
Yes, I live with my partner 160 30
Yes, I am in a relationship but do not live with my partner 86 16
No, I’m not in an ongoing relationship 293 54
Missing 1 0
a37% Europe, 13 % Africa, 12 % Central/South America, 12 % Asia, 12 % North
America, 10 % Australasia and 4 % missing
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course of PEP had been prescribed to 184 (34 %) partici-
pants in the past 12 months with 71 (13 %) having more
than one course.
Overall 50 % of participants reported more than one
strategy for managing their risk of contracting HIV. The
following strategies were reported: using condoms for
anal sex (n = 209; 39 %); choosing partners based on
their negative HIV status (n = 199; 37 %); strategic posi-
tioning (being ‘on top’ if they are unsure of partner’s
HIV status) (n = 157; 29 %); asking partners to use a con-
dom for anal sex (n = 134; 25 %); seeking partners who
are known to be on HIV treatment (n = 134; 25 %). Only
75 (14 %) participants reported that they did not think
about risk reduction strategies. MCA highlighted two
clear groups: 113 participants who exclusively reported
condom use (self or partner) and 206 who reported sero-
sorting or strategic positioning strategies. The other 131
participants used a combination of these strategies.
Participants were asked to self-categorise, into one of
five groups, their perceived risk of contracting HIV if
they have anal sex without using a condom: 8 (2 %) de-
scribed themselves as at no risk; 146 (27 %) at little risk;
258 (49 %) as somewhat at risk; 85 (16 %) as at high risk;
and 34 (6 %) at very high risk. Participants who considered
themselves somewhat at risk or higher (n = 377) were more
likely to have been diagnosed with syphilis, hepatitis C,
rectal gonorrhoea or rectal chlamydia in the past 12 months
(n = 151; 40 %) than those who considered themselves at
little risk or lower (n = 46; 28 %; p = 0.009).
Sexual risk behaviour
In the last 90 days, participants reported a median (IQR)
of 10 (5–20) partners with a range of 1 to >100. Of these,
a median (IQR) of 2 (1–5) were condomless partners
where the participant was receptive (bottom), and a me-
dian (IQR) of 2 (1–6) were condomless partners where
the participant was insertive (top). A median (IQR) of 7
(2–15) partners were new (partners a participant had not
had sex with before). In the last 90 days, 55 (10 %) partici-
pants had 40 or more partners and 59 (11 %) participants
had more than 10 condomless partners where the partici-
pant was receptive and 77 (14 %) had more than 10 con-
domless partners where the participant was insertive.
Participants reported a variety of reasons for not using
a condom at their last condomless anal sex act: it is
more enjoyable without a condom (n = 349; 65 %); I
don’t like using condoms (n = 268; 50 %); he doesn’t like
using condoms (n = 178; 33 %); condoms weren’t dis-
cussed (n = 140; 26 %); I was under the influence of
drugs (n = 128; 24 %) or alcohol (n = 113; 21 %); I didn’t
consider myself at risk of HIV (n = 115; 21 %); and we
don’t use condoms with each other but do with other
partners (n = 86; 16 %). MCA did not decompose re-
sponses to reasons for non-condom use into clear
groups. At the last condomless anal sex act 239 (45 %)
participants thought their partner was HIV-negative; 146
(28 %) thought their partner was HIV-positive and on
treatment; 118 (22 %) did not know the HIV status of
their partner; and 28 (5 %) thought he was HIV-positive
and either not on treatment or did not know.
Among the 467 participants who reported sexual be-
haviour in both the last 30 days and the last 90 days at
enrolment, participants typically reported more partners
per 30 days in the last 30 days (median = 5; IQR = 2–10)
compared to the last 90 days (median = 3; IQR = 2–7;
p <0.001). This pattern was also consistent for the
number of condomless partners where the participant
was receptive (median (IQR) = 1 (0–3) versus 1 (0–1);
Table 3 Self-reported history of, and diagnosed sexually transmitted infections at enrolment
Self-reported diagnoses (lifetime)a Self-reported diagnoses (last 12 months)b Diagnosed at enrolment
N % N % N %
Rectal gonorrhoea 174/532 33 126/478 26 12/251 5
Urethral gonorrhoea 216/538 40 112/480 24 2/256 1
Oral gonorrhoea 175/539 32 121/483 25 13/255 5
Rectal chlamydia 160/533 30 99/470 21 10/248 4
Urethral chlamydia 173/538 32 80/478 17 3/255 1
Oral chlamydia 63/523 12 60/471 13 3/244 1
Lymphogranuloma venereum (LGV) 15/127 12 10/458 2 0/7 0
Syphilis 110/537 20 49/473 10 13/237 5
Hepatitis C 9/451 2 3/464 1 0/132 0
Genital warts 168 - 45/472 10 6 -
Genital herpes 73 - 25/464 5 10 -
Notes
athe data for lifetime diagnoses were collected by staff during the enrolment interview and accounted for conditions that were never tested for
bthe data for diagnoses in the last 12 months were reported by participants on the questionnaire who were invited to indicate ‘yes’ or ‘no’ for each infection.
In the event that no answer was returned, they were not included in the denominator for that infection
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p <0.001) and insertive (median (IQR) = 1 (1–3) versus
1 (0–2); p <0.001).
Participants in the PROUD pilot study reported their
recreational drug use in the past 3 months: 394 (73 %)
had used recreational drugs during this period. Poppers
and Viagra were frequently used (n = 262; 49 % and n =
223; 41 % respectively). Other drugs used included:
mephedrone (n = 197; 36 %), GHB/GBL (gamma-hydro-
xybutrate or gamma-butyrolactone) (n = 169; 31 %), co-
caine (n = 139; 26 %), cannabis (n = 128; 24 %), crystal
methamphetamine (n = 98; 18 %), ecstasy (n = 90; 17 %),
ketamine (n = 89; 16 %) or some other drug (n = 92;
17 %). Drugs commonly associated with drug use in a
sexual context (ChemSex: mephedrone, GHB/GBL or
crystal methamphetamine) were used by 231/525 (44 %)
participants in the past 3 months.
London centres compared to out-of-London centres
Participants enrolled in the eight London-based clinics
(n = 375; 69 %) were compared to participants enrolled
in the five out-of-London clinics (n = 165; 31 %) to
evaluate differences in baseline demographics, STIs and
sexual risk behaviour. Participants in London were less
likely to be white (75 versus 86 %; p = 0.003) and more
likely to be Black-African, Black-Caribbean or mixed
race (10 versus 4 %; p = 0.023). Participants in London
were similar in age (median = 36 versus 35 years; p = 0.37)
to out-of-London participants. London participants were
more likely to be born outside the UK (50 versus 18 %;
p <0.001) and more likely to be university educated
(69 % versus 42 %; p <0.001). London participants had
more HIV and STI tests in the last 12 months (mean of
3.5 versus 2.9; p <0.001 and mean of 3.1 versus 2.7; p =
0.006 respectively) and more courses of PEP in the past
12 months (mean of 0.64 versus 0.41; p = 0.022). London
participants reported more diagnoses of STIs in the last
12 months than out-of-London participants (n = 243, 67 %
versus n = 88, 56 %; p = 0.018) and had significantly more
lifetime STI diagnoses (n = 342, 91 % versus n = 131; 80 %;
p = 0.001). Finally, London participants also reported a
higher total number of partners in the last 90 days
(mean = 17.3 versus 13.3; median = 10 versus 10; IQR =
5–20 versus 4–18; p = 0.023) and significantly more
condomless partners where the participant was inser-
tive (mean of 5.1 versus 3.7; median = 2 versus 1; IQR =
1–6 versus 1–5; p = 0.029). However, there was no sig-
nificant difference between London and out-of-London
participants in the number of condomless partners
where the participant was receptive (mean of 4.1 versus
3.7; median = 2 versus 2; IQR = 1–4 versus 1–4; p =
0.54) or the number of new partners (mean of 11.9
versus 9.3; median = 7 versus 6; IQR = 2–15 versus 1–11;
p = 0.15). London participants were more likely to have
used recreational drugs in the past 3 months (n = 287,
79 % versus n = 107, 66 %; p = 0.003).
GUMCAD clinic comparison
PROUD participant data were compared to data from
92,307 HIV-negative GMSM who attended a GUMCAD
clinic in 2013, of which 40,493 HIV-negative GMSM were
seen at participating PROUD clinics [22]. There were sig-
nificant differences in age between PROUD participants
and GUMCAD attendees, with more participants in
PROUD aged 34–44 (33 % versus 22 %; p <0.001) and
fewer aged 20–24 (9 % versus 19 %; p <0.001). The
ethnicity of PROUD participants appeared similar to
GUMCAD attendees (81 % versus 80 % white ethni-
city). PROUD participants were more likely to be born
outside the UK compared to GUMCAD attendees (40 %
versus 28 %; p <0.001), but were similar to GUMCAD at-
tendees at PROUD clinics (40 % versus 43 %; p = 0.22).
PROUD participants were more likely to have been re-
cruited from London than the general GUMCAD clinic
attendees (70 % versus 51 %; p <0.001). PROUD study par-
ticipants had attended clinic a mean of 3.27 times in the
past 12 months for an HIV test, compared to a mean of
1.13 for HIV-negative MSM attending GUMCAD clinics
in 2013.
Whilst not directly comparable measurements, the
number of STI diagnoses reported by PROUD partici-
pants is high in comparison to GUMCAD attendees.
Rectal chlamydia was diagnosed in 2454 (3 %) GUM-
CAD attendees in 2013 and 2244 (2 %) were diagnosed
with rectal gonorrhoea. There were a total of 585 pri-
mary syphilis diagnoses, 87 hepatitis C diagnoses and
107 LGV diagnoses in HIV-negative GMSM attending
GUMCAD clinics in 2013, all less than 1 %. PEP use also
appears high among PROUD participants compared to
the general GMSM population in England: in GUMCAD
clinics in 2013, there was a total of 4133 PEP prescrip-
tions in 92,037 HIV-negative GMSM (4.5 %).
Discussion
The PROUD study is the first randomised entirely open-
label study of PrEP with a deferral design that aims to
explore its real-world effectiveness, taking account of
changes in behaviour that may follow the use of a drug
known to reduce the risk of contracting HIV.
The baseline data presented here indicate that the
GMSM who enrolled in the PROUD study are at sub-
stantially higher risk of acquiring HIV infection sexually
than the overall population of GMSM attending sexual
health clinics in England. Our data demonstrate that the
PROUD cohort had several key indicators to support the
observation that they were at high risk of HIV acquisition,
particularly those recruited through the London centres.
This is consistent with data suggesting that people living
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in London tend to have poorer sexual health outcomes
[23, 24], are a population with higher rates of partner
change and higher use of ChemSex drugs [25]. These
indicators could inform discussions with potential PrEP
users in the UK. Further analysis is required to establish
whether these indicators are predictive of HIV infection
among the participants who seroconverted during the
study.
There is a striking excess of reported STIs in the
12 months preceding baseline in the PROUD cohort
compared to the number of infections diagnosed in the
general HIV-negative GMSM population attending
clinics in 2013. This difference is not directly compar-
able, due to participants’ 12-month history of STIs not
all occurring in 2013, and because diagnosed STIs are
per clinic whilst reported STIs may span several clinics
that a participant visits. Nonetheless, this difference sug-
gests that PROUD participants have particularly high rates
of STIs. Of note, a high proportion of the PROUD cohort
reported previous rectal infections. Rectal infections,
particularly with gonorrhoea and chlamydia, have been
associated with higher risk of HIV infection and it has
been suggested that a diagnosis of rectal STIs may be
used as one of a number of criteria for actively recom-
mending PrEP to GMSM clinic attendees [26]. Despite
this excess of STIs at baseline, only 22 % of participants
considered themselves to be at high or very high risk of
HIV in general when they last had anal sex without using
a condom. This highlights a limitation of this question as
perceived HIV risk at the last anal sex act without a con-
dom will vary by partner and may differ from a partici-
pant’s overall perceived risk of acquiring HIV.
Participants also reported high numbers of sexual part-
ners, particularly condomless sex partners. The PROUD
cohort reported a higher median number of partners in
the preceding 90 days, compared to that reported else-
where. For example, PROUD participants reported 10
partners versus 5 in the European EMIS survey of
MSM [27] and versus 3 in the US National Behavioural
Surveillance system survey [28]. In the Pre-exposure
Prophylaxis Initiative (iPrEx) study, eligible GMSM re-
ported an average of 7 sexual partners in the past 3 months
at baseline and an average of 18 sexual partners in the past
12 months [2]. The median number of condomless sex
partners reported in PROUD appears high in relation to
European and US surveys. In EMIS, 58 % of GMSM re-
ported at least one instance of condomless anal sex in the
past 12 months [27]. In a US survey, white and black
GMSM reported a median of two condomless anal sex
partners in the past 12 months [29]. Further work should
compare the distribution of the number of partners since
the median is of limited value.
There is concern about the role of recreational drugs in
facilitating condomless anal sex, leading to an increased
number of partners and the possibility of rectal trauma
after protracted periods of sexual activity. A survey of
ChemSex (sex under the influence of drugs) in south
London found that a third of men reported difficulty in
negotiating safe sex whilst under the influence of drugs
[25]. Although PROUD participants were not asked spe-
cifically about ChemSex, their use of recreational drugs in
the past 3 months, particularly drugs associated with
ChemSex such as mephedrone, crystal methamphetamine
and GHB/GBL, was much higher than previously reported
in national Internet surveys of GMSM [30] and the
general population in England and Wales [31].
The study population reported an eight-fold higher
use of PEP for sexual exposure in the past year when
compared to the national surveillance data, with 13 %
using it more than once. The costs associated with PEP
are substantial and include drug costs and frequent
clinic visits. Cost-effectiveness analyses need to be con-
ducted to determine if a PrEP programme could reduce
costs compared to PEP in a population with this level of
PEP usage.
PROUD participants used several other risk reduction
strategies such as condoms, serosorting and seroposi-
tioning. However, despite active risk management, in-
cluding using strategic positioning, three participants
had a reactive HIV antigen-antibody test at baseline,
despite a non-reactive antibody point-of-care test. These
recently acquired infections underscore the failure of
existing risk reduction strategies to prevent infection.
This is not surprising as the range of risk reduction
strategies employed prior to enrolment were selective,
either selective condom use or selection of partner and
type of sex to have without a condom. Follow-up data
from PROUD will provide an opportunity to assess how
men fit PrEP into their existing strategies.
Previous cost-effectiveness studies for PrEP suggested
that with current drug costs a daily PrEP programme
will only be of cost-benefit if provided to the population
most at risk of HIV [32–35]. Data from PROUD will in-
form decisions about commissioning of PrEP in England
[36] and UK cost-effectiveness analyses [37, 38]; these
concluded that daily PrEP, in a medium-sized PrEP roll-
out of 5000 GMSM, would only become cost-effective if
current drug prices are substantially reduced. The base-
line data suggest that it is feasible to deliver an effective
PrEP programme through the sexual health clinic net-
work. PROUD was a pilot study with very limited re-
sources and recruitment depended not only on clinical
providers identifying GMSM who would benefit from
PrEP, but also GMSM recognising their need for add-
itional options and informing others in their social and
sexual networks.
There are some limitations to this analysis. Although
data were available for the majority of participants at
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baseline, a small proportion of baseline data were miss-
ing. Efforts were made to contact all of these partici-
pants to collect basic demographic data. However, we
did not retrospectively collect behavioural data as this
would have been subject to recall bias. Recall bias may
also explain the difference in 90-day versus 30-day risk
assessment findings, with the suggestion that 90-day risk
assessment may underestimate more recent risk.
The PROUD population were highly educated; they
were older and more likely to have been born outside
the UK compared to the general GMSM population at-
tending GUM clinics in England, although were as equally
likely to have been born outside the UK as attendees from
the sexual health clinics in which they were recruited. The
PROUD population has a similar median age to the age of
first diagnosis among GMSM in England, which was
34 years in 2012 [39]. Due to the time lag between infec-
tion and diagnosis, this suggests that GMSM accessing
PrEP in PROUD are also older than the age of the general
GMSM population who seroconvert.
Black, Asian and minority ethnic (BAME) GMSM
populations were similarly represented in the PROUD
cohort compared to the population attending the same
GUM clinics in England but had higher representation
than the general GMSM population in England. Data
from the US, UK and Canada suggest that this ethnic
group is at highest risk of acquiring HIV and would
benefit from PrEP. This needs to be explored further in
the UK context where there are fewer disparities in ac-
cess to health care [40] but where differences in the use
of services remain [41].
PrEP was only offered in the PROUD study in major
urban centres, and may not have been accessible to those
living in more rural areas and in some parts of the country
where there were no PROUD centres. In addition, the
process of informed consent, randomisation to wait a year,
and participation in a study, in general, could have de-
terred many eligible GMSM from enrolling. This could
have contributed to the initial delay in recruitment to the
study and forthcoming quantitative and qualitative work
will describe the acceptability of the study in more detail.
There were also unanticipated delays getting all 13 recruit-
ment centres operational. Nonetheless, the rate of recruit-
ment increased over time as information about the trial
spread via word of mouth and the eventual population re-
cruited were at high risk of HIV, so benefited greatly from
the offer of PrEP.
Participants who enrolled in the PROUD study knew
that PrEP had proven biological efficacy and these re-
sults demonstrate that the population interested in PrEP
are likely to be highly self-selective for those at high risk
of HIV acquisition. We expect similar effectiveness in
populations with a lower risk of sexually acquiring HIV
if there are similar levels of adherence, although our
findings suggest that populations at low risk of HIV or
with low rates of STIs may be less interested in the offer
of PrEP if it becomes accessible as part of the NHS.
Nonetheless, there were some participants in PROUD
who had never reported an STI during their lifetime and
further research is ongoing examining any changes in
sexual risk behavior and STI diagnosis in this group.
Conclusion
Baseline data from the PROUD pilot study suggest that
it attracted a population of GMSM at high risk of HIV,
reflected in high rates of STIs and higher risk sexual
behaviours. These findings contribute to explaining the
extraordinary HIV incidence rate during follow-up. Despite
broad eligibility criteria, the population interested in PrEP
were highly selective and substantially benefited from
access to PrEP.
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